Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2017; 17(5):352-355
DOI: 10.5428/pcar20170510
Case analysis of thrombocytopenia in a patient after percutaneous coronary intervention
1. HOU Wei1(1. Department of Pharmacy,Changhai Hospital,Second Military Medical University,Shanghai 200433,China weiwei821338906@126.com)
2. 2( 2. Department of Pharmacy,Tianjin Hospital,Tianjin 300211,China )
3. CAO AiLin1(1. Department of Pharmacy,Changhai Hospital,Second Military Medical University,Shanghai 200433,China )
4. QIAN Jiao1(1. Department of Pharmacy,Changhai Hospital,Second Military Medical University,Shanghai 200433,China qianjiaosmmu@163.com)
5. CHEN WenYao3(3. Department of Cardiovasology,Changhai Hospital,Second Military Medical University,Shanghai 200433,China )
6. NI Min4(4. Department of Pharmacy,Shanghai Tenth People’s Hospital,Shanghai 200072,China )
7. SHI Yan5( 5. Department of Pharmacy,Dongfang Hospital Affiliated to Tongji University,Shanghai 200120,China )
ABSTRACT  Objective: To analyze the causes of thrombocytopenia after percutaneous coronary intervention (PCI) in a patient with coronary heart disease. Methods: The causes of thrombocytopenia after PCI were analyzed based on the medical history and medication history. The suspected drugs were assessed according to the evaluation criteria of relevance formulated by National Center for Adverse Drug Reactions(ADRs) Monitoring,and Naranjo ADRs scoring criteria. Results: Through medical history and one by one drug screening,thrombocytopenia was suspected to be induced by antiplatelet drug ticagrelor. The platelet count gradually recovered following abandonment of the drug. Clopidogrel and aspirin were then used to continue dual antiplatelet therapy,and the patient’s condition improved and was duly discharged. Conclusion: The thrombocytopenia of the patient might be caused by ticagrelor.
Welcome to PCAR! You are the number 137 reader of this article!
Please cite this article as:
HOU Wei1,2,CAO AiLin1,QIAN Jiao1,CHEN WenYao3,NI Min4,SHI Yan5,. Case analysis of thrombocytopenia in a patient after percutaneous coronary intervention[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2017; 17(5): 352-355.
References:
1. Amsterdam E A,Wenger N K,Brindis R G,et al.2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J].Circulation,2014,130(25): e344-e426.
2. HAN YaLing. China guidelines for percutaneous coronary artery intervention treatment(2016)[J].Chin J Cardiol,2016,44(5):382-400.In Chinese.
3. van Vuren A J,de Jong B,Bootsma H P,et al. Ticagrelor-induced renal failure leading to statin-induced rhabdomyolysis[J]. Neth J Med,2015,73(3):136-138.
4. Mosca M,Neri R,Bencivelli W, et al. Undifferentiated connective tissue disease: analysis of 83 patients with a minimum followup of 5 years[J]. J Rheumatol,2002,29(11):2345-2349.
5. Bodolay E,Csiki Z,Szekanecz Z,et al. Five-year follow-up of 665 Hungarian patients with undifferentiated connective tissue disease(UCTD)[J]. Clin Exp Rheumatol,2003,21(3):313-320.
6. Antón Vázquez V,Pascual L,Corominas H,et al. Relapsed hydroxychloroquine-induced thrombocytopenia in systemic lupus erythematosus patient[J]. Reumatol Clin,2017,13(5):294-296.
7. ZHONG Gang. Aspirin allergy associated with thrombocytopenia in 2 patients[J]. Sichuan Med J,2013,34(8):1282. In Chinese.
8. Karaku V,Deveci B,Kurtoglu E,et al. Early profound secondary autoimmune thrombocytopenia induced by clopidogrel in a patient with a coronary artery stent[J]. Turk J Haematol,2012,29(1):94-95.
9. Vedes E C,Marques L D,Toscano Rico M C. Severe isolated thrombocytopenia after clopidogrel and pentoxifylline therapy:a case report[J]. J Med Case Rep,2011,5:281.
10. HUANG NianXu,WANG Peng. Analysis of clinical medication in a patient with acute coronary syndrome complicated with thrombocytopenia[J]. J China Prescrip Drug,2015,13(9):31-32. In Chinese.
11. James S,A。kerblom A,Cannon C P,et al.Comparison of ticagrelor,the first reversible oral P2Y12 receptor antagonist,with clopidogrel in patients with acute coronary syndromes:Rationale,design,and baseline characteristics of the platelet inhibition and patient outcomes (PLATO) trial[J].Am Heart J,2009,157(4):599-605.
12. Gurbel P A,Bliden K P,Butler K,et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease:the ONSET/OFFSET study[J]. Circulation,2009,120(25):2577-2585.
13. WANG HeYang,SU Xi,SHEN ChengXing,et al.Effectiveness and safety of ticagrelor in acute coronary syndromes[J].Chin J Evid Based Cardiovasc Med,2015,7(4):468-471. In Chinese with English abstract.
14. LI ZhiHua,ZHANG YaChen,XIE YuQuan,et al.Clinical efficacy and safety of ticagrelor in acute coronary syndrome patients receiving percutaneous coronary intervention[J].Chin J Intervent Cardiol,2015,23(8):446-450. In Chinese with English abstract.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:PharmCR@vip.163.com
·技术支持:中国康网
管理员入口